



Accelero Initiates Formal Clinical Study at Breast Cancer Centre

Berlin, 15 September 2018

The company is pleased to initiate its first formal clinical study at one of the breast cancer centres in Berlin, Germany. The study is entitled “Post-operative wound fluid collected from female breast cancer patients” and has been approved by the clinical ethics committee.

This is the first time Accelero has been setting up a clinical study. A Berlin-based breast cancer centre has been contracted to provide human wound fluid for bioanalytical purposes. This will enable Accelero to support clients developing therapeutics for wound healing.

Accelero Bioanalytics GmbH is a GLP certified contract research service provider for regulatory drug development and maintains genetic engineering (bio)safety level 2 laboratories in compliance with ICH GCP regulations.

The business model focuses on – but is not limited to – the development of allogenic Advanced Therapy Medicinal Products (ATMP) in a regulatory context. The team provides bioanalytical support for living biotherapeutics (human cells, microbial cells), viruses (oncolytic, adeno-associated vectors, etc) or vaccines (DNA, plasmids, etc).

For additional information on our services, please feel free to use our contact form, or send us an email to [service\(at\)accelero-bioanalytics.com](mailto:service(at)accelero-bioanalytics.com). The Accelero team will be happy to assist you.

Accelero Bioanalytics GmbH
Center for Biotechnology and Environment
Volmerstrasse 9A
12489 Berlin
GERMANY

Primary Contact:
Christian Lange, Founder & Managing Director
Telephone +49 30 610 910 300

qPCR
Biodistribution
ELISA
EliSpot / FluoroSpot
Flow cytometry
Multiplex immunoassays
Multiplex miRNA assays
Cell culture
Microbiology
GLP trainings & seminars

Follow us on



Read binding-assay.com for blog and case studies.

